RediNews
ETFs Holding ALDR »    ALDR Historical Stock Prices »
ALDR News Video: Wed, Jul 19, 2017, 10:33 AM — Wednesday 7/19 Insider Buying Report: ALDR, EVLV


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Alder Biopharmaceuticals is a clinical-stage biopharmaceutical company. Co. is focusing its development efforts on eptinezumab (ALD403), its product candidate, which is being evaluated in a pivotal trial program for the prevention of migraine. Co.'s product candidate pipeline also includes ALD1910, a monoclonal antibody that targets pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), which is undergoing investigational new drug-enabling studies for the prevention of migraine. Co.'s third pipeline candidate is clazakizumab, designed to block the pro-inflammatory cytokine IL-6. Co. has licensed the worldwide rights to clazakizumab to Vitaeris, Inc. Self directed investors in Alder Biopharmaceuticals Inc will be interested in keeping up with all Alder Biopharmaceuticals Inc news they can find, both ALDR news originating from the company in the form of press releases, as well as seeing how independent media outlets are reporting news on ALDR. At RediNews, we simplify this task by presenting both ALDR news releases originating from Alder Biopharmaceuticals Inc itself, and ALDR news from a variety of media outlets. Visitors can browse this news online and through our ALDR RSS news feed.

ALDR News

ALDR News — Articles, Videos, & Press Releases

The Implied Analyst 12-Month Target For VBK
Thursday, May 16, 2019, 8:20 AM — ETF Channel
Investors Land ALDR Even Cheaper Than Its Secondary Stock Offering
Friday, May 10, 2019, 11:13 AM — Dividend Channel
First Week of June 21st Options Trading For Alder Biopharmaceuticals (ALDR)
Monday, April 29, 2019, 11:11 AM — Stock Options Channel
ESML's Holdings Could Mean 10% Gain Potential
Monday, April 15, 2019, 8:23 AM — ETF Channel
First Week of ALDR May 17th Options Trading
Wednesday, March 20, 2019, 10:58 AM — Stock Options Channel
Analysts Expect 45% Upside For XBI
Monday, March 11, 2019, 8:19 AM — ETF Channel
Ensign Group's (ENSG) Q4 Earnings Top Estimates, Surge Y/Y
Friday, February 8, 2019, 9:05 AM — Zacks
MEDNAX (MD) Q4 Earnings Surpass Estimates, Increase Y/Y
Friday, February 8, 2019, 9:03 AM — Zacks
Analysts See 61% Gains Ahead For XBI
Wednesday, January 30, 2019, 7:42 AM — ETF Channel
Notable Wednesday Option Activity: ALDR, PZZA, JPM
Wednesday, January 2, 2019, 3:17 PM — Stock Options Channel
Sum Up The Pieces: FYC Could Be Worth $54
Friday, December 28, 2018, 9:37 AM — ETF Channel
First Week of ALDR July 2019 Options Trading
Thursday, November 29, 2018, 10:45 AM — Stock Options Channel
Analysts Expect FYX To Hit $73
Tuesday, November 27, 2018, 7:37 AM — ETF Channel
Commit To Purchase Alder Biopharmaceuticals At $10, Earn 11% Annualized Using Options
Tuesday, November 20, 2018, 11:35 AM — Stock Options Channel
Implied PRFZ Analyst Target Price: $154
Friday, October 26, 2018, 7:31 AM — ETF Channel
Oversold Conditions For Alder Biopharmaceuticals (ALDR)
Friday, October 12, 2018, 11:48 AM — Dividend Channel
Analysts Forecast 11% Gains Ahead For FYC
Monday, September 24, 2018, 7:23 AM — ETF Channel
Alder Biopharmaceuticals Enters Oversold Territory
Wednesday, September 19, 2018, 4:23 PM — Dividend Channel
First Week of ALDR April 2019 Options Trading
Wednesday, August 22, 2018, 10:44 AM — Stock Options Channel
Short Sellers Drawn To These Five Louis Bacon Holdings
Friday, August 10, 2018, 11:19 AM — Dividend Channel
Implied FYX Analyst Target Price: $72
Tuesday, July 31, 2018, 7:44 AM — ETF Channel
5 Louis Bacon Holdings Attracting Short Sellers
Thursday, July 12, 2018, 10:19 AM — Dividend Channel
Implied FAD Analyst Target Price: $79
Thursday, June 28, 2018, 8:31 AM — ETF Channel
5 Louis Bacon Holdings Attracting Short Sellers
Tuesday, June 12, 2018, 2:16 PM — Dividend Channel
Louis Bacon Vs. The Shorts: Five Surprising Holdings
Friday, May 25, 2018, 2:35 PM — Dividend Channel
First Week of January 2019 Options Trading For Alder Biopharmaceuticals (ALDR)
Friday, May 25, 2018, 10:34 AM — Stock Options Channel
ALDR is categorized under the Healthcare sector; below are links to news for some other companies in the same sector:

HYH News
SURG News
LBIO News
AGRX News
OTIC News
CERU News
ZFGN News
AST News
CTSO News
ONCE News

RediNews invites those seeking web page financial content for any internet portal, especially any vertical portal specializing in the markets where there is a web page for business, web page for markets, web page finance, etc., to integrate our free web site content, our RSS news feeds. These RSS feeds are found throughout our website wherever news and custom stock content is found, by clicking the RSS icon for any news page (which will look like this): . This dynamic financial content is ideal for sites that already feature stock data content such as historical stock price information whether in the form of a historical stock price table or a web page chart image, to supplement the other custom stock market content displayed.

ALDR News | www.RediNews.com | Copyright © 2013 - 2019, All Rights Reserved

Nothing in www.RediNews.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.